Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company focused on developing innovative solutions for pain relief while minimizing opioid misuse, reported a net loss of $10.2 million for the year ended December 31, 2025, compared to a net loss of $8.0 million in the previous year. The increase in losses is attributed to heightened research and development expenses, which rose to $10.4 million from $7.2 million in 2024, primarily due to expanded clinical and preclinical programs for its lead product candidates, PF614 and PF614-MPAR. General and administrative expenses also saw a slight increase, totaling $4.9 million, up from $4.7 million in 2024.
The company generated $5.1 million in revenue from federal grants in 2025, a decrease from $5.2 million in 2024. This decline was primarily due to the conclusion of funding under the Opioid Use Disorder (OUD) grant, offset by increased funding from the Multi-Pill Abuse Resistant (MPAR) grant. Ensysce has not yet commercialized any products and does not expect to generate significant revenue from product sales in the near future, which raises concerns about its ability to continue as a going concern.
Ensysce is advancing its product pipeline, with PF614 currently in Phase 3 clinical development and PF614-MPAR in Phase 1b. The company has received Fast Track designation from the FDA for PF614 and Breakthrough Therapy designation for PF614-MPAR, which may expedite their development and review processes. However, the company acknowledges that regulatory approval is uncertain and contingent on successful clinical trial outcomes.
As of December 31, 2025, Ensysce had $4.3 million in cash and cash equivalents, which it expects will fund operations into the second quarter of 2026. The company anticipates needing substantial additional funding to support ongoing development activities and to address its liquidity needs. Ensysce's future viability is heavily dependent on its ability to raise capital, as it has incurred significant operating losses since its inception and does not expect to achieve profitability in the foreseeable future.
About Ensysce Biosciences, Inc.
Ensysce Biosciences is a clinical-stage pharmaceutical company developing innovative opioid and pain management solutions. Its proprietary TAAP and MPAR platforms create abuse-resistant and overdose-protective prodrugs, aiming to reduce misuse, overdose, and addiction. The company focuses on safer opioid products for pain relief and opioid use disorder, targeting markets with high societal impact, leveraging novel molecular delivery technologies to improve safety and efficacy.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.